Business Context and Reporting Period
Company: TherapeuticsMD, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 19, 2016
Reporting Period: Event-based report regarding regulatory milestones.
Key Financial Metrics
This filing is a Current Report on Form 8-K and does not contain audited financial statements, revenue figures, profit data, cash flow, margins, debt levels, or liquidity metrics. The document serves to disclose a specific corporate event rather than periodic financial performance.
Material Changes
The primary material event disclosed is the U.S. Food and Drug Administration (FDA) acceptance of the New Drug Application (NDA) for the company's product candidate, Yuvvexy (TX-004HR). Additionally, the FDA has assigned a Prescription Drug User Fee Act (PDUFA) date for the application.
Guidance, Outlook, and Risks
- Management Commentary: The filing references a press release (Exhibit 99.1) detailing the FDA acceptance and PDUFA date assignment.
- Forward-Looking Statements: The company expressly disclaims any obligation to release updates or changes to expectations regarding forward-looking statements contained in the report.
- Risks and Contingencies: No specific financial risks or contingencies are detailed in the text of this 8-K, other than the inherent uncertainty of regulatory review processes implied by the NDA submission.
Investor Verification Checklist
- Verify the specific PDUFA date assigned by the FDA for Yuvvexy (TX-004HR) by reviewing Exhibit 99.1 (Press Release).
- Confirm the status of the NDA review process and any potential for delays beyond the PDUFA date.
- Review the company's most recent 10-Q or 10-K filings for actual financial performance data, as this 8-K contains no financial metrics.
- Monitor subsequent filings for updates on the FDA's final decision regarding the NDA.